WallStSmart

Clene Inc. (CLNN)vsJBS N.V. (JBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JBS N.V. generates 65870262% more annual revenue ($88.27B vs $134,000). JBS leads profitability with a 2.0% profit margin vs 0.0%. JBS earns a higher WallStSmart Score of 45/100 (D+).

CLNN

Avoid

22

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -28.19

JBS

Hold

45

out of 100

Grade: D+

Growth: 4.7Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 6/9Altman Z: 2.62

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLNN2 strengths · Avg: 10.0/10
EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Debt/EquityHealth
-1.1710/10

Conservative balance sheet, low leverage

JBS3 strengths · Avg: 9.0/10
P/E RatioValuation
7.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 22 in profit

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

CLNN4 concerns · Avg: 2.8/10
Market CapQuality
$70.03M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1738.0%2/10

ROE of -1738.0% — below average capital efficiency

JBS4 concerns · Avg: 2.5/10
Profit MarginProfitability
2.0%3/10

2.0% margin — thin

Operating MarginProfitability
2.4%3/10

Operating margin of 2.4%

EPS GrowthGrowth
-57.2%2/10

Earnings declined 57.2%

Free Cash FlowQuality
$-6.99B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CLNN

The strongest argument for CLNN centers on EPS Growth, Debt/Equity.

Bull Case : JBS

The strongest argument for JBS centers on P/E Ratio, Return on Equity, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : CLNN

The primary concerns for CLNN are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : JBS

The primary concerns for JBS are Profit Margin, Operating Margin, EPS Growth. Debt-to-equity of 2.81 is elevated, increasing financial risk. Thin 2.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

JBS is growing revenue faster at 10.7% — sustainability is the question.

CLNN generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor PACKAGED FOODS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JBS scores higher overall (45/100 vs 22/100) and 10.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clene Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.

JBS N.V.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

JBS N.V., is a protein and food company globally. The company is headquartered in Amstelveen, Netherlands.

Want to dig deeper into these stocks?